<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897416</url>
  </required_header>
  <id_info>
    <org_study_id>5518</org_study_id>
    <secondary_id>FHCRC-5518</secondary_id>
    <secondary_id>CDR0000355401</secondary_id>
    <nct_id>NCT00897416</nct_id>
  </id_info>
  <brief_title>Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer</brief_title>
  <official_title>Validation of a Serum Marker Panel for Early Detection of Breast Cancer in High-Risk Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and storing samples of blood and studying them in the laboratory may&#xD;
      help doctors learn more about changes that may occur in DNA and identify biomarkers related&#xD;
      to cancer.&#xD;
&#xD;
      PURPOSE: This laboratory study is examining biomarkers in women with a high risk or average&#xD;
      risk of breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Identify and validate serum biomarkers that can distinguish malignant from benign and&#xD;
           normal breast conditions in women at high risk or average risk for breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Standardize procedures for recruitment, characterization, and follow-up of participants&#xD;
           and collection, processing, storage, and analysis of specimens.&#xD;
&#xD;
        -  Assess marker variability over time in healthy controls.&#xD;
&#xD;
        -  Develop a shared specimen resource to support ongoing early detection research.&#xD;
&#xD;
      OUTLINE: Blood samples are collected every 6 months and assayed for the presence of&#xD;
      biomarkers.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 625 participants will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker evaluation for the early detection of breast cancer to improve outcomes for women at risk for breast cancer</measure>
  </primary_outcome>
  <enrollment type="Actual">1452</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy women undergoing screening mammography or breast biopsy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Planning to undergo outpatient annual mammogram or biopsy AND meets 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  High risk for breast cancer&#xD;
&#xD;
               -  High risk with newly-diagnosed* breast cancer&#xD;
&#xD;
               -  Average risk for breast cancer&#xD;
&#xD;
               -  Average risk with newly-diagnosed* breast cancer&#xD;
&#xD;
               -  Benign breast disease NOTE: * Diagnosed at time of study enrollment&#xD;
&#xD;
          -  No other breast cancer diagnosis within the past year&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  25 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No hemophilia&#xD;
&#xD;
          -  No other bleeding disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  At least 6 months postpartum&#xD;
&#xD;
          -  No planned pregnancy within the next year&#xD;
&#xD;
          -  No history of medical conditions that would increase participant risk of blood draws&#xD;
&#xD;
          -  No psychiatric, psychological, or other condition that would preclude giving informed&#xD;
             consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior double mastectomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent treatment for breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Urban, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>November 5, 2010</last_update_submitted>
  <last_update_submitted_qc>November 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nicole Urban, ScD</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

